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Abstract
Clonal mosaicism for large chromosomal anomalies (duplications, deletions and uniparental
disomy) was detected using SNP microarray data from over 50,000 subjects recruited for genome-
wide association studies. This detection method requires a relatively high frequency of cells (>5–
10%) with the same abnormal karyotype (presumably of clonal origin) in the presence of normal
cells. The frequency of detectable clonal mosaicism in peripheral blood is low (<0.5%) from birth
until 50 years of age, after which it rises rapidly to 2–3% in the elderly. Many of the mosaic
anomalies are characteristic of those found in hematological cancers and identify common deleted
regions that pinpoint the locations of genes previously associated with hematological cancers.
Although only 3% of subjects with detectable clonal mosaicism had any record of hematological
cancer prior to DNA sampling, those without a prior diagnosis have an estimated 10-fold higher
risk of a subsequent hematological cancer (95% confidence interval = 6–18).
INTRODUCTION
Chromosomal mosaicism is the presence of different karyotypes in two or more cell lineages
within an individual derived from a single zygote1,2. This karyotypic variation may arise
early in development and involve both the soma and the germline or it may occur later and
be restricted to one or more specific cell types. In cancer, chromosomal anomalies can
initiate a neoplastic clone or arise during clonal evolution and serve as clonal markers3. Here
we consider such clonal variation as a form of mosaicism, since the cancer cells may have
acquired one or more chromosomal abnormalities, while other cells in the same tissue, or
elsewhere in the body, retain the normal karyotype. Chromosomal mosaicism in humans has
been well studied in embryos4,5, fetuses from spontaneous abortions6, children with birth
defects or developmental delay7,8 and cancer patients9. However, little is known about the
type, frequency and age distribution of acquired chromosomal anomalies in large samples
from the general population9,10.
Data from genome-wide association studies now provide an opportunity to detect
chromosomal variation in tens of thousands of people of all ages and to investigate the
association of mosaicism with disease. Single nucleotide polymorphism (SNP) microarray
data are used routinely to detect chromosomal anomalies (copy number variants (CNV) and
uniparental disomy (UPD)) in clinical cytogenetic laboratories11,12 and to detect small
CNVs in population studies13–15. However, the analytical methods used in population
studies are not optimized for detecting large anomalies or mosaicism. Therefore, we
developed an efficient method to identify and localize large (50 kb to whole-chromosome)
anomalies and mosaicism within a single DNA sample. This method requires a relatively
high frequency of cells (>5–10%) with the same abnormal karyotype (presumably of clonal
origin) in the presence of normal cells. Therefore, we use the term ‘detectable clonal
mosaicism’, rather than simply ‘chromosomal mosaicism’, to emphasize the observation of
clones of cells with abnormal karyotype that occur at a frequency sufficient for detection
using SNP microarray data.
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tDNA samples (primarily from peripheral blood) from over 50,000 people genotyped for the
Gene-Environment Association Studies (GENEVA) consortium16 were analyzed to detect
clonal mosaicism. The GENEVA studies include all ages from birth to old age, several
major ethnic groups, and a variety of different health conditions, including healthy controls
(Table 1, Supplementary Table 1, Supplementary Fig. 1). Here we characterize the types of
chromosomal anomalies detected, show how the prevalence of detectable clonal mosaicism
within blood cells increases with age, and examine the association between mosaic
anomalies and hematological cancer.
RESULTS
Types of anomalies detected
This report deals with autosomal anomalies, defined here as deviations from the normal
biparental disomic state. Anomalies were detected using log R ratio (LRR) and B Allele
Frequency (BAF)17. LRR is a measure of relative signal intensity (log2 of the ratio of
observed to expected intensity, where the expectation is based on other samples). BAF is an
estimate of the frequency of the B allele of a given SNP in the population of cells from
which the DNA was extracted. In a normal cell, the B allele frequency at any locus is either
0 (AA), ½ (AB) or 1 (BB) and the expected LRR is 0. Both copy number changes and copy-
neutral changes from biparental to uniparental disomy (UPD) result in changes in BAF,
while copy number changes also affect LRR (Figures 1 and 2). Our detection method
identifies both non-mosaic (constitutional) and clonal mosaic anomalies, which were
distinguished subsequently using standards based on parent-offspring transmission in family
studies and polymorphic CNVs in non-family studies. Three types of clonal mosaics were
detected: mixtures of disomic and monosomic cells (deletions), mixtures of disomic and
trisomic cells (duplications), and copy-neutral mixtures of biparental and acquired
uniparental disomy (aUPD) (see examples in Figure 3 and Supplementary Figure 2). The
aUPDs are primarily terminal segments, as expected for an origin through mitotic crossing
over (Supplementary Fig 3), while some cases of whole-chromosome aUPD may be due to
aneuploidy rescue (Supplementary Fig. 4).
Using a method optimized to detect large anomalies (50 kb to whole chromosome), we
identified at least one non-mosaic anomaly (i.e. large CNV) in 75% of all subjects, at least
one clonal mosaic anomaly in 0.80%, and both types in 0.69%. The median size of all
anomalies detected is 150 kb (Supplementary Fig. 5) and the mean number per subject is
1.5, with a range of 0 to 13. There were 514 mosaic anomalies in 404 of 50,222 subjects
analyzed.
The reproducibility (in 568 duplicate sample pairs) of all anomalies analyzed for mosaic
status is 82% (with >80% overlap; see Methods and Supplementary Table 2 for details). For
clonal mosaic anomalies in duplicate samples, the reproducibility is 15/22 = 68% and all
discordant calls appear to be false negatives, based on examination of BAF/LRR plots. We
also assessed the reproducibility of clonal mosaic anomaly calls in comparison with the
results of Jacobs et al.18, who analyzed the same raw data for 5,510 subjects from the
GENEVA Lung Cancer study. While both methods detected 83 mosaics, the GENEVA
method described here detected an additional 28 mosaics (8 > 2 Mb) and the Jacobs method
detected an additional 20 mosaics (all > 2 Mb). The overall reproducibility is 63% or, when
considering only anomalies greater than 2 Mb (the size-detection limit of the Jacobs
method), 75%. Both estimates are considerably greater than the 25–50% reproducibility
across methods estimated for several common CNV-calling algorithms19. All of the
discordant mosaic detections appear to be due to false negatives. The Jacobs method is more
conservative with respect to size threshold (2 Mb), while our method is more conservative
with respect to sample quality (but calling mosaics involving segments less than 2 Mb when
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tsample quality is sufficient). Therefore, the false negative rate of both methods appears to be
high and the prevalence of clonal mosaic anomalies detected here is likely to be
underestimated. Mosaic detection is difficult when the fraction of abnormal cells is extreme,
when the anomaly length is small or when sample quality is low (i.e. high BAF/LRR
variability).
The clonal mosaic anomalies detected in GENEVA subjects were classified as 15.6%
duplications, 50.4% deletions and 34.0% aUPDs. All three classes of mosaic anomalies are
large (Figure 4 and Supplementary Fig. 6). Median lengths are 34.1 Mb for duplications, 3.8
Mb for deletions and 39.8 Mb for aUPD. Mosaic aneuploidies include +8, +9, +12, +14,
+15, +18, +19, −21, and +22, while whole-chromosome mosaic UPDs include chromosomes
2, 3, 13, 14, and 15. Plots of the breakpoints of all mosaic anomalies are provided in
Supplementary Figure 7 and genomic coordinates (along with other information) are
provided in Supplementary Table 3.
There is a highly significant excess of subjects with multiple clonal mosaics, compared to
the Poisson distribution expected if the anomalies occurred independently. The multiples are
of two kinds: (a) ‘compound’ sets of anomalies adjacent to one another on a single
chromosome, suggesting a single event or related mechanism of origin (e.g. Supplementary
Figure 2g) and (b) non-adjacent sets. Among the 404 mosaic subjects, 64 had multiple
mosaics of one or both types (while 2.6 were expected) and 55 had only non-adjacent sets
(2.4 expected). The excess of multiple mosaics occurs for both CNVs and aUPD. The age of
subjects with multiple anomalies is not significantly different than those with a single
anomaly (p=0.99).
The frequency of detectable clonal mosaicism increases with age
The observed frequency of subjects with one or more clonal mosaic anomalies detected
(‘mosaic status’) is shown in Figure 5 and Supplementary Table 4. It is low (< 0.5%) in
subjects less than 50 years old, but increases thereafter to 2.7% in subjects over 80. The
mosaic frequency is 0.2% in both the 0–14 (15/8535) and 15–29 year old group (16/6739),
despite the fact that approximately half of the 0–14 year old subjects have a phenotypic
abnormality (non-syndromic cleft lip/palate, prematurity or low birth weight). Excluding
subjects less than 15 years old, in multiple logistic regression of mosaic status on age at
DNA sampling, and adjusting for several covariates (study, sex, DNA source, and ethnicity),
age is a highly significant predictor of mosaic status (p = 2 × 10−16, odds ratio=1.05, 95%
confidence interval (CI)=1.04 – 1.07). Among the covariates, only study is significant
(p=0.01) and a subsequent test of age-by-study interaction was not significant. It is notable
that DNA source (92% from blood, 8% from saliva/buccal swabs) was not a significant
predictor (p=0.45). When only blood samples are analyzed, the age effect estimate is the
same (to three decimal places) and the p-value is only slightly higher (4 × 10−15). Copy-
number mosaics and aUPD, when tested separately, each have a significant age effect and
similar odds ratios (p-value for gain=0.01, loss=5 × 10−11, aUPD=6 × 10−8; OR (95% CI)
for gain = 1.032 (1.005 – 1.061), loss = 1.057 (1.039 – 1.075), aUPD = 1.056 (1.035 –
1.077).
This age effect is specific for mosaic anomalies. The same logistic regression performed
with the non-mosaic anomalies did not have a significant age effect (p=0.11) and the sign of
the regression coefficient estimate was reversed (Supplementary Figure 8). This result
indicates that our classification method distinguishes effectively between acquired and
constitutional anomalies.
To further explore the robustness of the age effect on clonal mosaicism, additional analyses
were performed with each of the seven studies having more than 1,000 subjects over 50
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tyears old (using both blood and saliva/buccal samples). Only the age effect was significant
(p=8 × 10−16) in a combined logistic regression of mosaic status on study, sex, DNA source,
ethnicity and smoking status (separately testing either ‘ever’ smoker or ‘never’ smoker).
When only controls from these studies were analyzed together, the age effect remained
highly significant (p=7 × 10−11). We also analyzed each study separately, with age and the
case status specific to each study. A meta-analysis shows a highly significant effect of age
(Figure 6), which is very robust to differences in both study and subject characteristics.
These cross-sectional analyses strongly suggest that most of the mosaic anomalies detectable
by SNP microarrays appear late in life, because they arise more frequently and/or because
they are more readily detected due to clonal expansion. This suggestion is supported by
longitudinal observation in one GENEVA subject (the only subject sampled twice who had
mosaicism in at least one sample). This subject was sampled at age 66 and again at age 72
(both with DNA from saliva). No mosaic anomalies were detected in the earlier sample, but
the later sample contained 5 mosaic deletions, each on a different chromosome. Additional
studies with subjects sampled at multiple ages are needed to evaluate the temporal origin
and stability of mosaic anomalies.
In some GENEVA subjects, anomalies appear to have occurred early enough in
development to be mosaic in both the soma and germline. In 35 parent-offspring pairs in
which a mosaic anomaly was detected in the parent, there are three cases in which the
offspring appears to be non-mosaic for the same anomaly (one deletion and two
duplications), while there is no corresponding anomaly (mosaic or otherwise) in the
remaining 32 offspring. Although this result suggests that a fairly large fraction of cases
have mosaicism shared by the germline and soma, it may not be representative of the more
frequent mosaics that occur in older subjects because parents in the family studies were
sampled in their 20s and 30s (Table 1). The mosaics that appear in subjects less than 50
years of age may have different origins than those that appear later, when the frequency
increases rapidly.
Mosaic anomalies characteristic of hematological cancers
The clonal mosaic anomalies detected in this study tend to cluster in location both within
and among chromosome arms (Figure 4; Supplementary Fig. 7 and 9). Regions with
multiple overlapping anomalies frequently coincide with regions of copy number change or
aUPD characteristic of hematological cancers. Using the Mitelman "Recurrent Chromosome
Aberrations in Cancer Database" (http://cgap.nci.nih.gov/Chromosomes/Mitelman), we
found that 222 of 669 recurrent duplications and deletions found in hematological cancers
have >80% overlap with at least one mosaic CNV in GENEVA subjects. Also, 77% of
GENEVA mosaic CNVs have >80% overlap with the Mitelman aberrations and 48%
overlap both cytological bands defining the limits of the aberration. The most common
overlaps are 20q-, 13q-, 11q-, 17p-, 12+ and 8+.
Common deleted regions (CDR) of mosaic anomalies in different GENEVA subjects often
pinpoint genes previously associated with the hematological cancers. The following
examples are shown in Supplementary Figure 7: (1) On 13q, 31 deletions have a CDR of
299 kb, containing only one gene, DLEU7, which is thought to be a tumor suppressor20. In
addition, 18 deletions on 13q cover RB1 and 24 cover MiR15a and MiR16-1. Deletions in
this region (13q14) represent the most common cytogenetic abnormality in chronic
lymphocytic leukemia (CLL)21, which is the most common leukemia in older adults (http://
seer.cancer.gov). (2) On 4q, 14 deletions have a CDR of 214 kb containing only one gene,
the TET2 oncogene, which is commonly deleted in myelodysplastic syndrome (MDS),
myeloproliferative disorder (MPD) and acute myeloid leukemia (AML)22. (3) On 2p, 17
deletions have a CDR of 194 kb, which contains two genes, one of which is DNMT3A,
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trecently found to be commonly mutated in AML-M523. (4) On 22q, 11 deletions have a
CDR of 153 kb, which includes three genes, one of which is PRAME, which is frequently
deleted in CLL24. (5) On 20q, 46 deletions have a CDR of 965 kb, containing 7 genes
including L3MBTL1, which is a candidate tumor suppressor in del(20q12) myeloid
disorders25.
Long (multi-megabase) segments of aUPD are frequently observed in cancers of many
types26. In most cases, the UPD occurs on a terminal segment of one arm, consistent with
origin by a single mitotic crossover, followed by outgrowth of one of the daughter cells.
Acquired UPDs are frequently observed in hematological cancers such as MDS, MPD and
AML and are associated with homozygosity of mutations in several tumor suppressors and
oncogenes27,28. All autosomes (except chromosome 10) have at least one clonal mosaic
aUPD in GENEVA subjects. Chromosomes 9 (with 24), 14 (with 21) and 11 (with 19) have
the most aUPDs, which greatly exceed the expected number based on arm length
(Supplementary Figure 9).
Despite the observation that many of the clonal mosaic anomalies observed here are
characteristic of hematological cancer, the fraction of subjects with one or more mosaics
who have a record of hematological cancer before DNA sampling is low. This fraction was
estimated as 2.8% (95% CI=1.0 – 4.7%) in 291 mosaic subjects (with DNA from blood;
from 13 GENEVA studies; using medical records, self-reported conditions and study
exclusion criteria, as described in the Supplementary Note).
Hematological cancer incidence
We investigated whether detectable clonal mosaicism predisposes to incident hematological
cancer after DNA sampling by using three GENEVA studies, which included cohorts with
cancer diagnosis records both before and after DNA sampling. From the following studies,
we analyzed 8,562 subjects who had DNA derived from blood and no record of
hematological cancer prior to DNA sampling: (1) Glaucoma study, with subjects from the
Nurses Health Study (NHS, N=363) and Health Professionals Follow-up Study (HPFS,
N=285), (2) Lung Cancer study, with subjects from the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial (PLCO, N= 1600) and (3) Prostate Cancer study, with
subjects from the Multiethnic Cohort (MEC, N=6314). Among the 8,562 subjects analyzed
for incident hematological cancer, 8,323 were non-mosaics with no events, 90 were non-
mosaics with events, 134 were mosaics with no events, and 15 were mosaics with events
(where ‘event’ is a hematological cancer diagnosis).
To test for an association between mosaic status and incident hematological cancer, we used
a cause-specific Cox proportional hazards model to analyze time to a hematological cancer
diagnosis from the date of DNA sampling, with right censoring at death and the endpoint of
follow-up data. We performed a stratified analysis of the four cohorts, which included
mosaic status and adjusted for age at DNA sampling, non-hematological cancer status (as a
time-dependent covariate), ethnicity (two principal components) and sex (within the PLCO
stratum). The hazard ratio estimate for mosaic status is 10.1 (95% CI=5.8 – 17.7) with a p-
value of 3 × 10−10. A meta-analysis showed consistent results among cohorts and gave a
very similar effect estimate (Supplementary Figure 10). These results estimate that the risk
of hematological cancer is ten-fold higher for mosaic than for non-mosaic subjects.
Because both cancer and the clonal mosaic anomalies detected in this study increase with
age, the adjustment for age at time of DNA sampling in the Cox regression model is critical.
We modeled the age covariate as either a linear effect or as a non-linear effect (spline
smoothing with 5 degrees of freedom) and found that the mosaic effect estimates and p-
values are essentially identical.
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had myeloid leukemia, six had chronic lymphocytic leukemia, one had multiple myeloma,
one had MDS, one had MPD and two had non-Hodgkin lymphoma. Thus, the 15 cases are
about evenly divided between mature B-cell neoplasms and myeloid malignancies. Not
surprisingly, the leukemias are over-represented among mosaic compared with non-mosaic
subjects (p-value=0.005, Supplementary Tables 5 and 6). A variety of chromosomal
anomalies were found in the mosaic subjects (Supplementary Table 7). Deletions covering
the CDRs described above were found in several of these subjects: 13q- in five CLLs, 4q- in
one chronic myelogenous leukemia (CML), 20q- in one multiple myeloma and one AML,
and 22q- in one CLL. Five of the 15 mosaic subjects with incident hematological cancer had
more than one mosaic anomaly, which is higher than in the remaining subjects within this
set of cohort samples (25/134), although not significantly so (p=0.18).
Although the risk of incident hematological cancer is estimated as 10-fold higher for mosaic
than for non-mosaic subjects (95% CI=5.8 – 17.7), it is important to note that the incidence
rate in mosaics is low (10 year event rate of 0.143, 95% CI=0.065 – 0.214, Figure 7) and
that only a small fraction of GENEVA mosaic subjects have a record of hematological
cancer before DNA sampling (2.8%, 95% CI=1.0 – 4.7%). The period between first
appearance of detectable clonal mosaicism and incidence of hematological cancer is of
interest, but cannot be estimated from our data since mosaicism was present for an unknown
period of time prior to DNA sampling. However, the median time of 3.5 years between
DNA sampling and hematological cancer diagnosis provides a very rough minimum
estimate (range 3.5 months to 10.7 years with N=15; see Figure 7).
Non-hematological cancer
To investigate the relationship between mosaic status and non-hematological cancer, two
types of analyses were done. First, in each of the three GENEVA case-control cancer studies
(Lung Cancer, Prostate Cancer, Melanoma), we did logistic regression of mosaic status on
case status and age at DNA sampling. Case status was not significant in any of the three
studies or in a meta-analysis (one-tailed p=0.06). The estimated odds of having a clonal
mosaic anomaly was higher among cancer cases than controls in the lung and prostate
cancer studies, but lower in the melanoma study (Supplementary Fig. 11). Second, in the
cohort studies (PLCO, HPFS, NHS and MEC), we did logistic regression of mosaic status
on whether or not the subject had a non-hematological cancer prior to DNA sampling
(excluding any hematological cancer cases). In these analyses the relationship is consistently
positive, but small and not significant overall (one-tailed p=0.11, Supplementary Figure 12).
In summary, the evidence hints at a positive relationship between mosaic status and non-
hematological cancer, but lacks statistical significance. Therefore, further work is needed in
larger sets of non-hematological cancer studies, including data on potential exposure,
disease and treatment effects.
DISCUSSION
Here we have shown that the frequency of subjects with detectable clonal mosaicism for
large chromosomal anomalies in peripheral blood is low (<0.5%) from birth until 50 years of
age, after which it rises rapidly. This relationship between mosaicism and age is very robust
to both study and subject characteristics. Among the covariates sex, ethnicity, smoking and
disease status (exclusive of hematological cancer), none had a significant effect on mosaic
status. The age effect in GENEVA subjects is consistent with a recent study showing that
acquired differences in structural chromosome variants between members of monozygotic
twin pairs (including clonal mosaic anomalies) are observed in pairs >55 years of age but
not in younger pairs29. Nevertheless, longitudinal studies are required to rule out the
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increase in mosaicism with age.
The observed increase in detectable clonal mosaicism late in life may be due to a change in
the frequency with which chromosomal anomalies occur (i.e. increased somatic mutation
rate) and/or their ability to form large clones (i.e. clonal expansion). Previous work has
shown that the occurrence of chromosomal anomalies (rearrangements and aneuploidies)
during cell division increases with age in cultured lymphocytes and fibroblasts30,31, that
DNA damage accumulates with age in mouse hematopoietic stem cells32, and that mitotic
recombination (leading to uniparental disomy) increases with replicative age in yeast33. This
apparent increase in somatic mutation may result from age-related decline in genomic
maintenance mechanisms (such as telomere attrition34). Clonal expansion of cells containing
chromosomal anomalies could be due to either positive selection or to random changes in
the frequencies of hematopoietic stem cell descendants. In principle, stem cell senescence
and age-related decline in replicative function35 could result in a decrease in the effective
population size of stem cells, leading to shifts in clonal composition analogous to random
drift in small populations of individuals36. However, analyses of the clonal composition of
blood cells, based on X-inactivation markers in healthy women, suggest stability over time
and between lymphoid and myeloid lineages, even in the elderly37,38. Therefore, in most
cases, positive selection may be required to establish clones of cells with chromosomal
anomalies that are sufficiently large for detection with SNP microarrays. The potential for
positive selection may increase with age as somatic mutations accumulate in genes that
regulate cellular proliferation. For example, a highly proliferative clone may arise when a
recessive tumor suppressor mutation becomes hemizygous in combination with a deletion,
or homozygous due to aUPD. This suggestion is supported by the observation that acquired
anomalies tend to cluster in certain genomic regions and that common deleted regions
pinpoint genes previously associated with hematological cancer.
In the mosaics described in this study, the chromosomally abnormal cells constitute a
significant fraction of white blood cells, since a minimum of 5–10% is required for detection
by our method and many abnormal clones are substantially larger (Figure 2). The blood
samples used for DNA extraction were not fractionated by white blood cell type. The
abnormal blood cells within an individual may include multiple cell types if the anomaly
arose in a multipotent hematopoietic stem cell that became predominant due to senescence
or positive selection within the stem cell population. Alternatively, the abnormal cells may
include a restricted set of cell types, particularly when the normal composition of blood (i.e.
60–70% of neutrophils and 20–40% of lymphocytes39) is altered by unregulated
proliferation40.
There is a strong association between the clonal mosaic anomalies detected in our study and
hematological cancer. We estimate the risk of acquiring a hematological cancer diagnosis as
10-fold higher for subjects with mosaic anomalies. This association is strongly supported by
finding that many of the mosaic anomalies are characteristic of those found in hematological
cancers. Nevertheless, the event numbers analyzed here are small and additional studies are
needed across a broader diversity of cohorts to establish the clinical significance of these
findings.
Notwithstanding the strong association with hematological cancer, we estimated that ~97%
of subjects with clonal mosaic anomalies did not have a record of a hematological cancer
prior to DNA sampling and the incidence rate is low (~ 14% over ten years in subjects who
survive and are not lost to follow-up during this period). These results suggest that the clonal
mosaicism observed in elderly subjects may be an asymptomatic condition with a
predisposition to hematological cancer that is often not realized.
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monoclonal B-cell lymphocytosis (MBL), an asymptomatic condition with an estimated
prevalence of 3–5% in the elderly. MBL is characterized by a clonal population of B
lymphocytes with an immunophenotype similar to CLL or other B-cell malignancy41. Most,
if not all, cases of CLL are preceded by MBL, but most cases of MBL do not progress to
malignancy42,43. However, 85% of MBL detected in population screening studies have a B-
cell count below 500/μl43, which is less than 10% of the normal white blood cell count.
Since 10% is near the lower limit of detection for chromosomal mosaicism using our
methods, the two types of clones may not be closely related. Nevertheless, further work on
the relationship between B cell immunophenotypes and mosaic anomalies is warranted.
Although it appears that most of the clonal mosaicism observed in GENEVA subjects
represents a non-malignant condition, further work is needed to evaluate the fraction of
subjects who might have unrecorded malignant conditions such as MDS and MPD, or
undiagnosed CLL. MDS and MPD were added to the Surveillance, Epidemiology, and End
Results (SEER) cancer registries in 2001 and may still be under-recorded because they are
often managed outside of the hospital setting44. Therefore, accurate prevalence data from
widespread populations are not available, but local population estimates (0.1% MDS45 and
0.5% MPD46 in the elderly) are substantially less than the ~2.5% of GENEVA subjects with
mosaic anomalies in the over 75 age.
This survey is the first large-scale study of acquired chromosomal anomalies in people of all
ages and various states of health. Previously, the extent of chromosomal variation within
developmentally normal individuals, in the absence of overt cancer, was largely unknown.
The results presented here indicate that a significant fraction of blood cells in people without
a prior history of hematological cancer may contain large chromosomal anomalies,
including multi-megabase deletions, duplications and aUPD. The frequency of people with
such clonal anomalies in a mosaic state is low up to about 50 years of age and then increases
rapidly up to 2–3%. We find that these anomalies are associated with an approximately ten-
fold higher risk of hematological cancer, but subjects with detectable clonal mosaicism may
survive for years without having a hematological cancer diagnosis. Further work is needed
to determine the stability of the mosaic state over time, to replicate and improve estimates of
the predisposition to hematological cancer, and to identify anomalies associated with
asymptomatic cancer precursor conditions. It also will be important to explore the health
consequences of these anomalies for conditions other than cancer, such as immune system
function.
METHODS
Study subjects, phenotypic data and genotyping
Subjects were recruited for 15 different studies belonging to the Gene Environment
Association Studies (GENEVA) consortium16 (Table 1). Each study was approved by the
institutional review board of the study investigator’s institution, and all subjects provided
written informed consent for participation in the study. The Supplementary Note describes
the phenotypes. Each study was genotyped on one of five different Illumina array types at
the Center for Inherited Disease Research (CIDR), the Broad Institute Center for
Genotyping and Analysis, or the University of Southern California (Supplementary Table 1).
DNA samples were derived from blood (92%) or saliva/buccal swabs (8%). No
lymphoblastoid cell line or whole-genome amplified samples were included in the analyses
described here. Because cell lines may have artifactual mosaic anomalies47, mis-
identification of DNA source is a concern. However, only the Addiction study had both cell
line and non-cell line samples and the non-cell line samples analyzed here did not have an
unusual frequency of mosaic anomalies. Genotypic data cleaning and calculation of BAF
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tand LRR are described in the Supplementary Note. Sample sizes for analyses vary (as stated
in Results) because a small proportion of the subjects are missing data for age at DNA
sampling or other variables.
Anomaly detection and quality control
The method of anomaly detection is described in detail in the Supplementary Note and
summarized here. Detection of anomalies (both mosaic and non-mosaic) was based on BAF
and LRR metrics. The primary focus for detecting anomalies was BAF, because we wanted
to identify copy-neutral events (mosaic UPD) and because BAF is much less noisy and
prone to artifacts (such as GC waves48) than LRR. The main approach was to detect a split
in the BAF intermediate band, which in normal (biparental disomic) samples is centered at
1/2 and corresponds to AB heterozygotes (Figure 1). In trisomic samples, this band splits
into two components (AAB and ABB) at BAF= 1/3 and 2/3. In disomic-trisomic mosaics,
the width of the split varies from zero to one third and LRR varies from zero to a theoretical
value of log2(3/2). In disomic-monosomic mosaics, the width of the split varies from zero to
one and LRR varies from 0 to a theoretical value of log2(1/2). In biparental-uniparental
disomic mosaics, the width of the split varies from zero to one, while LRR remains constant
at zero. These transitions are shown in Figure 2 as deviations from expected. In
chromosomal regions containing heterozygous SNPs, use of BAF alone can detect
duplications (both mosaic and non-mosaic), mosaic deletions, mosaic uniparental disomy
and homozygous deletions. LRR is required to detect monosomic regions and duplications
in regions lacking heterozygosity. Therefore, we implemented two separate but
complementary methods, called ‘BAF’ and ‘LOH’ (the latter for LRR change detection in
regions lacking heterozygosity). Anomalies detected by the BAF method were classified as
mosaic or non-mosaic. Anomalies detected by the LOH method were used here only to
define the BAF/LRR position of heterozygous deletions and not for mosaic detection. We
did not attempt to identify non-mosaic segments of uniparental isodisomy, which have no
heterozygosity and normal LRR.
In the BAF method, Circular Binary Segmentation (CBS)49 was used to detect change points
in a metric modified from Itsara et al.15: sqrt(min(BAF,1-BAF,|BAF -median(BAF)|)) for
SNPs called as missing or heterozygotes (i.e. excluding homozygotes). The use of missing
calls allows detection of wide splits (e.g. Figure 3d). In the LOH method, CBS was applied
to LRR values and combined with overlapping runs of homozygosity. By focusing on
regions of homozygosity, we avoided a high false positive rate associated with a genome-
wide search for changes in LRR. In both methods, the identification of anomalous segments
involved establishing a non-anomalous baseline, choosing anomalous segments based on
deviation from baseline, and applying quality control filters. Computations were done using
the Bioconductor packages DNACopy and GWASTools. The latter was developed by our
group; relevant functions are described in the Supplementary Note.
Quality control (QC) was done at the sample and anomaly level. Low quality samples (with
high variance of BAF and/or LRR metrics or a high level of segmentation) were removed
differentially for the two methods. Supplementary Table 1 shows the percentage of samples
that passed QC for the BAF method (mean = 99.1%) and the LOH method (86.8%). In some
studies, a high fraction of samples failed QC for LOH detection (maximum 47%), but the
failure rates for BAF-detection (from which all mosaics were identified) are all low
(maximum 8%). Anomaly-level QC involved several steps, including manual curation of all
anomalies designated as mosaic and all other anomalies greater than 2 Mb in length. (see
Supplementary Note). Manual curation involved evaluation of BAF/LRR plots, as shown in
Figure 3 and Supplementary Fig. 2. Note that Supplementary Fig 2(m-t) shows a sample of
eight of the smallest mosaic deletions. Features that distinguish mosaic from non-mosaic are
described in the Figure 3 legend.
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(N = 568 pairs). For each sample pair, we defined a unit of observation as a contiguous
chromosomal region containing an anomaly in one or both samples. Each unit is given a
score equal to the length of the intersection divided by the length of the union of anomalies
in that unit. A reproducibility measure was defined as the fraction of units with a score
greater than either 0.30 or 0.80 (chosen for comparison with published CNV studies). We
also calculated the average of the scores that were greater than zero. Supplementary Table 2
summarizes these quantities for each study. For BAF, the mean reproducibility measure was
90% with a 30% overlap threshold and 82% with 80% overlap. For LOH, the means were
71% (30% overlap) and 67% (80% overlap). The mean of scores greater than zero was 95%
for BAF- and 96% for LOH-detected anomalies (30% threshold), indicating that when an
anomaly is detected in both scans, the breakpoints are highly reproducible. These
reproducibility estimates are higher than the 40–60% that is typical for detecting CNVs
using Hidden Markov Models (HMM)19,50, perhaps in large part because we do not attempt
to detect small anomalies (the 5th percentile of anomalies we detect is 35 kb). In our
experience, standard methods of CNV detection, such as PennCNV51, tend to break up large
anomalies into many segments and to miss large mosaics.
Identifying and classifying clonal mosaic anomalies
Clonal mosaic anomalies were identified in GENEVA family studies by using transmitted
anomalies to characterize the bivariate BAF/LRR distribution expected for non-mosaic
(constitutional) anomalies. For transmitted anomalies, this distribution is approximately
bivariate normal within a study and we used this distribution to estimate a 95% prediction
ellipse52, which defines an area likely to contain most of the constitutional anomalies
(Supplementary Figure 13). Among the anomalies used to identify mosaics, the majority are
3N duplications. There is also a small cluster of 4N anomalies, but we did not attempt to
detect 3N/4N mosaics. Anomalies outside of these two clusters contain mosaics and
artifacts. The latter consist of false positives and anomalies with inaccurate breakpoints
(which distorts the median BAF/LRR values). To distinguish between the mosaics and
artifacts, we performed a manual review of BAF/LRR plots for all anomalies that fell
outside of the 95% prediction ellipse and below the mean LRR for anomalies used to define
the ellipse. The non-family studies were analyzed in a similar way, except that we replaced
the class of transmitted anomalies with polymorphic CNVs. The latter were defined by
hierarchical clustering to identify sets of anomalies with similar breakpoints. We then
defined polymorphic sets as those with at least 4 members (but excluding sets with mean
anomaly length greater than 10 Mb). We also included in the mosaic class three whole-
autosome anomalies (12, 8, 22) that fell within the 3N ellipse, because constitutional
trisomies for these chromosomes are not compatible with normal development1. Although
we did not have access to biospecimens necessary for experimental validation of mosaics
(i.e. live cells or those preserved for cytology), all anomalies classified as mosaics were
manually reviewed and the BAF/LRR patterns that we observed are very similar to those
reported by Peiffer17, Rodriguez-Santiago53 and Conlin7, who performed cytological
validation for a variety of mosaic types.
Classification of clonal mosaic anomalies as duplication, deletion or aUPD was done using
the median LRR and BAF deviations from non-anomalous segments (Figure 2b). Deviations
from non-anomalous segments within the same sample were used to control for overall LRR
variation among samples and for BAF asymmetry that occurs in some samples. Anomalies
that are either terminal segments or whole chromosome and that have an LRR deviation
within a ‘neutral zone’ (|LRR|<0.05) were classified as aUPD. This neutral zone was chosen
because it includes nearly all of the wide splits (BAF deviation > 0.25) that have much
smaller LRR deviations than expected for disomic/trisomic or disomic/monosomic
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ttransitions, while including very few interstitial anomalies (Supplementary Figure 3). All
other anomalies (except for a few outliers) were classified as either duplications or deletions,
depending on the sign of their LRR deviation. There is some ambiguity in classifying
anomalies near the tip of the arrow, where the three transition zones intersect. This
ambiguity is noted as ‘intensity.flag’ in Supplementary Table 3. Mixture proportions in
mosaics can be estimated as position along the transitional line that connects the two
constitutional states (Figure 2; see Supplementary Note).
All anomalies discussed in this paper are autosomal in the reference genome. Detection of X
chromosome mosaics is complicated by the fact that LRR is a measure of the intensity of a
sample relative to other samples. X chromosome LRR values (calculated in the standard
way) are affected by the sex ratio in the sample set and are not comparable to those for the
autosomes.
Statistical analysis
All statistical analyses were done in the R statistical package (http://www.R-project.org)
using functions described in the Supplementary Note.
URLs
http://cgap.nci.nih.gov/Chromosomes/Mitelman, Mitelman, F., Johansson, B. & Mertens, F.
(eds.). Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, (2011).
http://seer.cancer.gov, SEER. US Estimated 33-Year L-D Prevalence Counts on 1/1/2008.
(ed. Surveillance, E., and End Results (SEER) Program, National Cancer Institute, DCCPS,
Surveillance Research Program, Statistical Research and Applications Branch, released
April 2011, based on the November 2010 SEER data submission.) (2011).
http://www.R-project.org, The R Development Core Team, R: A language and environment
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN
3-900051-07-0, URL. (2006).
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tFigure 1.
Expected values of B Allele Frequency (BAF) and Log R Ratio (LRR) for discrete copy
number states. Mosaics have intermediate positions between these discrete states. Copy
number is given above the horizontal lines in the LRR plot, while SNP genotypes are given
in the BAF plot. M=maternal and P=paternal chromosome. States with M and P reversed are
also possible. The scatter of points for copy number = 0 (homozygous deletion) represents
background signal noise.
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tFigure 2.
Expected and observed values of B Allele Frequency (BAF) and Log R Ratio (LRR) metrics
for clonal mosaic anomalies detected in GENEVA subjects. (a) Expected. (b) Observed
(N=514). In (b), “med”=median, “anom”=within the anomaly, “nonanom”=non-anomalous
autosomal regions of the same sample. The solid purple and red circles represent the mean
values of non-mosaic anomalies and the solid black and cyan circles are theoretical.
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tFigure 3.
B Allele Frequency (BAF) and Log R Ratio (LRR) plots of four representative mosaic
anomalies. Each pair of plots is for a different sample-chromosome combination and each
point is a single SNP. Points in BAF plots are color-coded by genotype (red=AA, cyan=AB,
purple-blue=BB, black=missing call). The vertical black lines indicate the breakpoint(s) of
the anomaly. The vertical gray rectangle is the centromeric gap. Horizontal pink lines are
drawn at 0, 1/3, 1/2, 2/3 and 1 in the BAF plots. The solid horizontal red line in each plot is
the median value for non-anomalous regions of the autosomes. The horizontal dashed red
line is the median value within the anomaly. (a) Mosaic acquired uniparental disomy for
distal 12q is indicated by the split in the intermediate BAF band along with the lack of
change in LRR. A non-mosaic uniparental isodisomy would have only two BAF bands (at 0
and 1). (b) Mosaic trisomy for chromosome 19 is indicated by a narrow split in the
intermediate BAF band along with a small elevation of LRR. A non-mosaic trisomy would
have a wider BAF split (at 1/3 and 2/3) and a larger elevation of LRR. (c) A mosaic deletion
on 20q is indicated by a narrow split in the intermediate BAF band along with a small
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tdecrease in LRR. A non-mosaic heterozygous deletion would have no intermediate BAF
bands and a larger decrease in LRR. (d) A mosaic deletion on 6q is indicated by a wide split
in the intermediate BAF band along with a large decrease in LRR. The mosaic deletion in
(d) has a greater proportion of cells containing the deletion than the one in (c). See
Supplementary Figure 2 for additional examples.
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The lengths and chromosomal positions of the 514 clonal mosaic anomalies detected in
GENEVA subjects. An ideogram of each autosome is shown with scaled and color-coded
representations of each mosaic anomaly to the right.
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tFigure 5.
The percentage of subjects having one or more mosaic anomalies within 5-year age bins.
Vertical bars are 95% confidence intervals. For two cells with zero counts, the upper bar
connects zero to the frequency with a lower 95% confidence interval of zero given the
sample size. Expected leukemia values are given for reference and calculated using age- and
sex-specific prevalence estimates (http://seer.cancer.gov).
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tFigure 6.
Fixed-effects meta-analysis for effect of age at DNA sampling on mosaic status. Effect
estimates are from logistic regression of mosaic status on age at DNA sampling, with
adjustment for case status specific to each study. The summary estimate of the log odds ratio
is 0.05 (95% CI=0.04 – 0.07) and the corresponding odds ratio is 1.06 (95% CI=1.04 –
1.07). Cochran’s Q test of heterogeneity has p-value=0.89. The sizes of the black boxes are
proportional to the inverse of the squared standard error and the gray lines are 95%
confidence intervals. The horizontal points of the diamond span the 95% confidence interval
of the summary estimate. See Table 1 for study descriptions. AA = African American and JL
= Japanese/Latino.
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tFigure 7.
A Kaplan-Meier plot of the proportion of living subjects who remain free of hematological
cancer as a function of time since the time of DNA sampling and determination of mosaic
status. Estimates for mosaic (red) and non-mosaic (black) subjects are given separately
(solid lines), each with their 95% confidence intervals (dashed lines). The vertical ticks
represent censoring times. For the 15 mosaic subjects with incident cancer, the times
between DNA sampling and diagnosis are 3.5, 6.1, 12.7, 18.8, 25.0, 36.9, 37.5, 42.9, 44.0,
46.2, 48.0, 60.4, 61.8, 91.1, and 130.5 months.
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